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Abstract
Intermolecular recombination is the foundation for dual vector mediated larger gene transfer by recombinant adeno-associated virus
(rAAV). To identify precursors for intermolecular recombination, we sequentially infected skeletal muscle with AAV LacZ trans-splicing
viruses. At 1 month postinfection, nearly all inputting single-strand (ss) AAV genomes were cleared out in muscle. If ss–ss interaction is
absolutely required for intermolecular recombination, LacZ expression from sequential infection will be negligible to that from coinfection.
Interestingly, expression from sequential infection reached 50% of that from coinfection at the 1-month time-point in BL6 mice. In
immune deficient SCID mice, expression from sequential infection was comparable to that from coinfection at the 4- and 13-month time
points. Our results suggest that ds interaction represents the predominant pathway for AAV intermolecular recombination.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Recombinant adeno-associated virus (rAAV) is a single
strand (ss) DNA viral vector (Carter, 2000). Both sense ()
and anti-sense () strands are packaged in mature virions at
the equal efficiency (Berns and Rose, 1970). This vector
system has attracted great attention for gene therapy in
recent years. AAV-mediated gene expression depends on
the conversion of ss viral genome to the double strand (ds)
transcriptionally competent form. We have found that the
viral genome circularization is an important pathway to
form ds genomes in normal skeletal muscle (Duan et al.,
1998). Based on the detailed analysis of junction sequences
(Duan et al., 1999) and the previous electron-microscopic
characterization of AAV genome structure (Berns and
Kelly, 1974; Koczot et al., 1973), we have proposed an
inverted terminal repeat (ITR)-mediated recombination
model for the circular AAV genome formation. In this
model, the uncoated ss AAV genomes are organized as
panhandle-like ss circular structures. The handle is formed
by a hydrogen-bond interaction between the 5 and the 3
ITRs (Berns and Kelly, 1974; Koczot et al., 1973). Subse-
quent recombination between ITRs and the second strand
synthesis generate ds circular AAV genomes (Duan et al.,
1999) (Fig. 1A). Although it lacks direct experimental ev-
idence, this model gives a conceivable explanation for the
formation of a unique double D ITR structure at the junc-
tions of circular AAV genomes (Duan et al., 1999). The
long-term AAV-mediated gene expression seems to corre-
late with the formation of head-to-tail intermolecular circu-
lar concatamers (Duan et al., 1998; Yang et al., 1999). We,
as well as several other groups, have applied this novel
observation to the development of dual vector strategies to
expand AAV packaging capacity (Duan et al., 2000, 2001;
Nakai et al., 2000; Sun et al., 2000; Yan et al., 2000).
However, the exact molecular pathways underlying AAV
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intermolecular concatamerization remain to be defined. A
study using two AAV viruses, one carrying the EGFP
gene and the other carrying the alkaline phosphatase
gene, demonstrated the existence of covalently linked
circular AAV concatamers capable of expressing both
transgenes (Yang et al., 1999). This finding suggests that
the intermolecular recombination, rather than the rolling
circle replication, is responsible for the large circular
AAV concatamer formation. However, it is not clear
which type of AAV genome (ss or ds) is the molecular
substrate for intermolecular recombination. Based on the
model depicted in Fig. 1A (Duan et al., 1999), we hy-
pothesize that the interaction of the ITR sequences be-
tween independent ss viral genomes may also mediate
intermolecular recombination and the subsequent ds cir-
cular concatamer formation (Fig. 1B) (Berns and Kelly,
1974; Duan et al., 1999). This ss precursor model pre-
dicts an absolute requirement of ss–ss interaction for
AAV intermolecular recombination. On the other hand,
size fractionation of the circular AAV genomes at differ-
ent time points postinfection has provided indirect evi-
dence for the potential interaction and recombination
between ds circular monomers (Duan et al., 1998). The
larger circular concatamers were not formed early after
infection. Rather, they appeared at a later time (Duan et
al., 1998), likely as a result of the recombination between
ds circular monomers (Fig. 1C). Alternatively, the larger
circular concatamers can be produced by the head-to-tail
recombination between the preformed ds linear mono-
mers (Fig. 1D). A third possibility of intermolecular
recombination involves the interaction between ss and ds
genomes (Fig. 1E). These two models (ds– ds and ss– ds
interaction) also lack direct experimental evidence. Fur-
thermore, it is not clear how such interactions lead to the
formation of the unique double D ITR structure at the
concatamer junction.
To test whether ss–ss interaction is absolutely required
for intermolecular recombination, we performed a sequen-
tial infection experiment with our recently described AAV
LacZ trans-splicing vectors. The AV.LacZDonor contains
the RSV promoter, 5 LacZ gene, and a splicing donor
signal. The AV.LacZAcceptor carries a splicing acceptor
signal, 3 LacZ gene, and a poly A signal (Duan et al.,
2001). Functional LacZ protein can only be generated
through splicing across the ITR junction in donor/acceptor
heteroconcatamers. If AAV intermolecular recombination is
absolutely dependent on the ss AAV genome interaction, we
will expect no or very little LacZ expression following
sequential infection of the trans-splicing viruses, because
by the time of the second vector administration a great
majority of the ss AAV genomes from the previous infec-
tion may have already been converted to ds forms or been
cleared out by cellular enzymes and will not be available for
ss–ss viral genome interaction. In contrast, if ss–ss interac-
tion is not an essential step for intermolecular recombina-
tion, we will expect to see a reasonably high level LacZ
expression from sequentially delivered donor and acceptor
vectors. In this case, the heterodimers might be derived
from intermolecular recombination among ds genomes (Fig.
1C and D) or between ds and ss genomes (Fig. 1E).
Fig. 1. Schematic outline of different models of AAV genome recom-
bination. (A) A hypothetical single strand (ss) precursor model for
double strand (ds) circular AAV monomer formation. Recombination
between the 5 and the 3 ITR, subsequent second strand synthesis, and
religation lead to the formation of the characteristic double D structure
at the junction. The 5 ITR is marked by the arrowhead to distinguish
it from the 3 ITR. (B to E) The ss–ss, ds– ds, and ss– ds interaction
models for AAV intermolecular recombination. (B) The ss precursor
model. Similar to ss precursor model for circular AAV monomer
formation, recombination at the ITR between different AAV genomes
leads to the formation of circular heteroconcatamers. The boxed regions
in A and B highlight the ITR mediated recombination. (C) The circular
ds precursor model. In this model, ss AAV genomes form independent
ds circular monomers first. Subsequent recombination between two ds
circular monomers leads to the formation of ds circular dimer. (D) The
linear ds precursor model. In this model, ss AAV genomes form
independent ds linear monomers first. The ds circular dimers are de-
rived from end-to-end recombination between two ds linear monomers.
(E) The ss– ds interaction model. In this model, ss AAV genomes
interact with either circular or linear ds genomes to form ds circular
heteroconcatamers. Molecular mechanisms of ds AAV circular mono-
mer and concatamer formation remain to be clarified (indicated by
question marks). The two independent AAV genomes are presented in
black and gray, respectively, in B to E. The graphs are not drawn to
scale.
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Materials and methods
Recombinant AAV production
The cis-plasmids for rAAV production have been de-
scribed before (Duan et al., 1998, 2001). The recombinant
type-2 rAAV was used in all the experiments described in
this paper. Virus was prepared with triple plasmid transfec-
tion method as described by Xiao et al. (1998).
Animal procedure, AAV genome analysis, and reporter
gene assay
All animal experiments were carried out in accordance
with NIH and institutional guidelines. To analyze the ki-
netic of AAV genome metabolism, 3  1010 particles of
AV.EGFPori3 virus were delivered to tibialis anterior (TA)
muscles of 8-week-old C57/BL6 and SCID mice. The low-
molecular-weight Hirt DNA and the muscle genomic DNA
were examined by Southern blot according to our published
protocol (Duan et al., 1998, 2003). The densitometric quan-
tification of ss AAV genomes was performed with NIH
Scion Image 1.62 software. To test the ss–ss interaction
model, 5  109 particles of AV.LacZAcceptor were either
coinfected at the same time with AV.LacZDonor (5  109
particles/muscle) or administrated at 1 month after
AV.LacZDonor infection. LacZ expression was quantified
at the indicated time points by both the histochemical X-gal
staining and the -galactosidase activity assay as described
before (Duan et al., 2001).
Results
The kinetics of ss AAV genome metabolism in muscle
A critical parameter in this sequential infection experi-
ment is the time gap between two infections. An ideal
scenario would be to deliver the second vector at a time
when all the ss AAV genomes from the first infection are
cleared out or converted to ds forms. Several studies showed
that ss AAV genomes were barely detectable at 1 month
postinfection in murine skeletal muscle (Clark et al., 1997;
Vincent-Lacaze et al., 1999). To test whether the 1-month
waiting period was indeed an optimal time for the second
vector administration, we examined the kinetics of AAV
genome metabolism at 3, 14, and 30 days postinfection in
BL6 and SCID muscles. As shown in Fig. 2, ss AAV
genomes were substantially diminished by 30 days postin-
fection and they were barely detectable in BL6 muscles. By
6-weeks-postinfection, only ds genomes were detected; ss
genomes were no longer detectable by Southern blot (data
not shown) (Duan et al., 2003). Densitometry was used to
quantify kinetic changes of ss genomes. To facilitate the
comparison, we defined the ss genome signals at 3 days
postinfection as 100%. The loss of ss genome signal be-
tween days 0 and 3 was not quantified. By 30 days postin-
fection, ss AAV genomes in BL6 and SCID muscles were
only 0.44 (0.18) and 1.24 (0.35) % of what they were at
the 3-day time point, respectively (Fig. 2B). This study
suggested that a 1-month gap in sequential infection should
clear the vast majority of ss AAV genomes.
Trans-splicing mediated LacZ expression from coinfection
and sequential infection of LacZ trans-splicing viruses
To determine whether ss–ss genome interaction is abso-
lutely essential for AAV intermolecular recombination,
AV.LacZAcceptor was either coinfected with AV.LacZDonor
or administered at 1-month after AV.LacZDonor infection.
Consistent with our previous high dosage experiments (Duan
et al., 2001, 2003), coinfection of both AV.LacZDonor and
AV.LacZAcceptor led to comparably high-level LacZ expres-
sion in both BL6 and SCID muscles (Fig. 3). Surprisingly,
high-level LacZ expression was also achieved from sequen-
tially delivered AV.LacZDonor and AV.LacZAcceptor. At 1
month after AV.LacZAcceptor infection, sequential infection-
mediated LacZ expression reached 50% level of that from
coinfection in both BL6 (54.41 19.98%) and SCID (56.81
15.71%) muscles (Fig. 3A and B). These data strongly argue
against the ss precursor model (Fig. 1B).
Previous studies have shown that AAV-2 infection in-
duces the neutralization antibody against AAV-2 capsid
protein and this viral capsid-specific antibody can block the
second AAV-2 virus infection. This humoral immune-re-
sponse mediated inhibition of readministration can be
avoided by transient immune suppression, alternative route
of viral administration, or different AAV serotypes (Chir-
mule et al., 2000; Halbert et al., 2000; Xiao et al., 2000). As
shown in Fig. 3A, we also observed a diminished LacZ
expression in sequentially infected BL6 muscles. We hy-
pothesized that the low-level LacZ expression was due to
immune blockage of the second AAV infection, rather than
due to the lack of ss AV.LacZDonor precursors.
To further demonstrate that the ds genome interaction
may represent the predominant pathway for AAV intermo-
lecular recombination, we performed an identical experi-
ment in the immune-compromised SCID mice. Studies have
suggested a decreased circular AAV genome formation in
SCID muscle (Duan et al., 2003; Song et al., 2001). How-
ever, the alteration in the equilibrium between linear and
circular AAV concatamers did not seem to affect long-term
trans-splicing mediated gene expression (Duan et al., 2003).
Since SCID mice will not generate neutralization antibody,
the sequentially delivered AV.LacZAcceptor will success-
fully infect muscle cells. If ds–ds interaction is responsible
for AAV intermolecular recombination, we would expect to
see a comparable level of LacZ expression following se-
quential infection and coinfection. As shown in Fig. 3B and
C, we indeed observed a comparable level of LacZ expres-
sion in SCID mice. The method of administrating trans-
splicing AAV vectors, either simultaneously or separately,
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did not affect the overall level of LacZ expression, espe-
cially at late time points. Statistical analysis (Student t test)
revealed no difference between coinfection and sequential
infection at the 4- (P  0.86) and 13-month time points (P
 0.25).
Discussion
In this study, we have taken a unique sequential infection
strategy to determine the molecular substrates for AAV
intermolecular recombination. Three types of precursor
Fig. 2. Time course of ss AAV genome conversion in murine skeletal muscle. The AAV genome metabolism in mouse skeletal muscle was examined by
Southern blot with EGFP-specific probe at 3, 14, and 30 days postinfection. (A) The representative Southern blot results in BL6 and SCID mice samples.
The ss AAV genomes migrate at 1.6 kb. The circular ds monomer, the linear ds monomer, and the linear ds dimer are also marked by arrowheads. (B)
The densitometric quantification of ss AAV genome (mean  SEM; n  6 to 10 independent samples). The decrease of ss AAV genome from days 0 to
3 was not analyzed. The amount of the ss AAV genome at the 3-day time point was assigned as 100%.
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Fig. 3. Effect of viral administration protocol on trans-splicing AAV vector-mediated -galactosidase expression in BL6 and SCID muscles. (A) Relative
-galactosidase activity in BL6 muscles from codelivered and sequential delivered AV.LacZDonor and AV.LacZAcceptor viruses at 1, 4, and 13 months
postinfection (mean  SEM, n  6). In the coinfection group, the time points are after both AV.LacZDonor and AV.LacZAcceptor virus infection. In the
sequential infection group, the time points are relative to the second vector AV.LacZAcceptor virus infection. (B) Relative -galactosidase activity in SCID
muscles from codelivered and sequential delivered AV.LacZDonor and AV.LacZAcceptor viruses at 1, 4, and 13 months postinfection (mean  SEM, n 
6). (C) Representative photomicrographs of en face X-gal stained muscle samples from the 13-month time point.
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models were hypothesized based on the suggestive evidence
from previous studies (Berns and Kelly, 1974; Duan et al.,
1998, 1999; Koczot et al., 1973; Yang et al., 1999). These
include recombination between ss AAV genomes (Fig. 1B),
recombination between ds AAV genomes (Fig. 1C and D),
and recombination between ss and ds AAV genomes (Fig.
1E). Using trans-splicing AAV vector-mediated expression
as a functional end-point, we compared the level of LacZ
production from the simultaneously administrated
AV.LacZDonor and AV.LacZAcceptor and the sequentially
delivered AV.LacZDonor and AV.LacZAcceptor.
Despite the fact that the vast majority of ss AAV ge-
nomes were metabolized at 1 month postinfection, the se-
quentially delivered LacZ trans-splicing viruses still yielded
a high level of LacZ reconstitution. It reached50% of that
from coinfection at the 1-month time point in BL6 muscle
and was comparable to that from coinfection at the 4- and
13-month time points in SCID muscle. This piece of evi-
dence strongly suggests that ds–ds interaction is most likely
responsible for the AAV intermolecular recombination. In
support of this hypothesis, we have recently found that the
linear ds self-complementary AAV genomes were capable
of head-to-tail recombination (data not shown). This pre-
liminary observation is consistent with the ds precursor
model (Fig. 1D).
Numerous studies from our group and others have shown
that only a small, critical fraction of ss AAV genomes is
converted to the functional ds genomes while the majority
of ss AAV genomes are cleared out by cellular enzymes
(Fig. 2). Similarly, this critical pool of ss AAV genomes
may also be responsible for AAV intermolecular recombi-
nation. Our kinetic study revealed a substantial loss of
ssAAV genomes after infection. Less than 0.44 and 1.24%
of incoming ssAAV genomes were detected at 1 month
postinfection in BL6 muscle and SCID muscle, respec-
tively. Since ssAAV genomes are no longer detectable by 6
weeks postinfection, we reason that the residual ssAAV
genomes observed at the 1-month time point may represent
the dead-end products of AAV infection which will be
cleared out eventually. Therefore, they are unlikely to play
a significant role in intermolecular recombination.
Although our results did not exclude the ds–ss interac-
tion as a potential pathway, we suspect that this may not be
the case. During a normal infection (single AAV infection
or dual vector coinfection), the incoming genomes are pro-
cessed simultaneously, and the likelihood of ds–ds interac-
tion is much higher than ds–ss interaction. Furthermore, if
ds–ss interaction is solely responsible for the heterocon-
catamer formation, the maximal level of LacZ expression
from the sequentially delivered AAV trans-splicing viruses
will also be limited by the amount of ss AAV genomes.
The finding that AAV genomes form head-to-tail het-
eroconcatamers has greatly expanded the potential of
rAAV-mediated gene therapy for inherited diseases that are
caused by mutations in larger genes. Dual vector strategies
have been proposed for such diseases including cystic fi-
brosis, Duchenne muscular dystrophy, and hemophilia A.
Despite the promising future of the dual vector approaches,
the level of gene expression from the current dual vector
systems may not be sufficient for gene therapy (Duan et al.,
2001). A clear understanding of the molecular mechanisms
of AAV intermolecular recombination is essential for im-
proving the transduction efficiency of the dual vector me-
diated gene transfer. Our results have begun to shed light on
molecular processes leading to the AAV heteroconcatamer
formation.
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